Online citations, reference lists, and bibliographies.
← Back to Search

Impact Of Maximal Cytoreductive Surgery Plus Regional Heated Intraperitoneal Chemotherapy (HIPEC) On Outcome Of Patients With Peritoneal Carcinomatosis Of Gastric Origin: Results Of The GYMSSA Trial

Udo Rudloff, R. Langan, J. Mullinax, Joal D. Beane, S. Steinberg, Tatiana H Beresnev, Carole C. Webb, M. Walker, M. Toomey, D. Schrump, P. Pandalai, A. Stojadinovic, I. Avital
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
A prospective randomized trial was conducted to compare the impact of systemic chemotherapy versus multi‐modality therapy (complete cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and systemic chemotherapy) on overall survival (OS) in patients with gastric carcinomatosis.
This paper references
10.1200/JCO.2003.04.187
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
V. Verwaal (2003)
10.1007/978-1-4613-1247-5_23
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.
P. Jacquet (1996)
10.1097/CAD.0b013e3283273509
Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer
W. Cao (2009)
10.1200/JCO.1997.15.1.261
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
A. Webb (1997)
10.1002/JSO.20157
Re: Verwaal VJ, van Tinteren H, Ruth SV, et al.: Toxicity of cytoreductive surgery and hyperthermic intra‐peritoneal chemotherapy. J Surg Oncol 2004; 85:61–67
P. Sugarbaker (2004)
10.1200/JCO.2004.08.026
Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial.
H. Hartgrink (2004)
10.1245/s10434-010-1039-7
Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy
O. Glehen (2010)
10.1245/s10434-007-9487-4
A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer
T. Yan (2007)
10.1001/ARCHSURG.139.1.20
Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer.
O. Glehen (2004)
10.1093/ANNONC/MDL317
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
J. Lee (2007)
10.1016/j.gassur.2003.12.014
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer
J. J. Hall (2007)
Clinical delivery system for intraperitoneal hyperthermic chemotherapy.
J. S. Spratt (1980)
10.1093/ANNONC/MDH470
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
G. Masi (2004)
10.1245/s10434-011-1631-5
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial
X. Yang (2011)
10.1016/j.ejso.2007.12.003
Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience.
S. Scaringi (2008)
Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells.
B. Teicher (1981)
10.1002/bjs.4695
Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion
Y. Yonemura (2005)
patients with peritoneal carcinomatosis
I Avital (2000)
10.1002/JSO.20013
Toxicity of cytoreductive surgery and hyperthermic intra‐peritoneal chemotherapy
Vic J. Verwaal (2004)
10.1002/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy
D. Elias (2001)
10.1200/JCO.2004.01.140
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.
O. Bouché (2004)
10.1056/NEJMoa1011923
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
T. Conroy (2011)
10.1002/SSU.10042
Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer.
P. Sugarbaker (2003)
10.1056/NEJMOA055531
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
D. Cunningham (2006)
10.1245/s10434-008-9966-2
8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer
V. Verwaal (2008)
10.1200/JCO.2006.08.0135
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
A. Roth (2007)
10.14670/HH-20.543
Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma.
J. Y. Kim (2005)
10.1097/01.sla.0000197382.43208.a5
Clinical Outcomes With Laparoscopic Stage M1, Unresected Gastric Adenocarcinoma
A. Sarela (2006)
10.1002/1097-0142(20000601)88:11<2512::AID-CNCR12>3.0.CO;2-J
Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis
A. Beaujard (2000)
10.1245/s10434-009-0478-5
Safety of Gastric Resections During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis
P. Piso (2009)
10.1002/jso.23276
HIPEC + EPIC versus HIPEC‐alone: Differences in major complications following cytoreduction surgery for peritoneal malignancy
Y. McConnell (2013)
10.1136/gut.2010.226092
Stromal biology and therapy in pancreatic cancer
A. Neesse (2010)
10.1080/00015458.2006.11679897
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Carcinomatosis: Higher Complication Rate for Oxaliplatin Compared to Mitomycin C
A. Rouers (2006)
10.1016/j.soc.2012.07.004
Randomized clinical trials for colorectal cancer peritoneal surface malignancy.
I. Avital (2012)
10.1200/JCO.2000.18.14.2648
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of
U. Vanhoefer (2000)
10.1002/bjs.5863
Learning curve of combined modality treatment in peritoneal surface disease
R. M. Smeenk (2007)
10.1093/jnci/djp058
Diffuse-Type Gastric Carcinoma: Progression, Angiogenesis, and Transforming Growth Factor β Signaling
A. Komuro (2009)
10.1073/pnas.0611660104
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling
M. Kano (2007)
10.3109/0284186X.2011.594809
Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer
Bo Hultman (2012)
10.1245/s10434-011-1632-4
Hyperthermic Intraperitoneal Chemotherapy in Advanced Gastric Cancer: The End of Skepticism?
O. Glehen (2011)
10.1186/1745-6215-10-121
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone
S. Kerkar (2009)
10.1053/EJSO.2000.1021
Multimodal treatment of peritoneal carcinomatosis and sarcomatosis.
P. Pilati (2001)
10.1007/BF00299188
Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer
Y. Yonemura (2004)
Intraperitoneal chemo-hyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis.
A. C. Sayag-Beaujard (1999)
10.1002/jso.23228
Treatment‐related morbidity and toxicity of CRS and oxaliplatin‐based HIPEC compared to a mitomycin and doxorubicin‐based HIPEC protocol in patients with peritoneal carcinomatosis: A matched‐pair analysis
G. Glockzin (2013)
10.1093/ANNONC/MDF019
Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.
D. Elias (2002)



This paper is referenced by
10.1007/978-981-10-7053-2_14
Intraperitoneal Chemotherapy for Gastric Cancer
M. Jain (2018)
10.1016/j.jss.2019.03.036
Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis.
A. Paredes (2019)
10.3978/j.issn.2078-6891.2015.111
Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy.
Martin D. Goodman (2016)
10.21037/TGH.2020.02.06
Advances in the surgical management of gastric and gastroesophageal junction cancer
Raja R. Narayan (2020)
10.1016/j.suronc.2019.01.005
HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits?
Thomas Hotopp (2019)
10.21037/jgo.2017.09.01
Heated intraperitoneal chemotherapy and gastrectomy for gastric cancer in the U.S.: the time is now.
Zachary J Brown (2017)
10.1007/s00104-020-01112-y
S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs
S. Moenig (2020)
10.4251/wjgo.v10.i11.398
Conversion surgery for gastric cancer patients: A review
T. Zurleni (2018)
10.7150/jca.30821
Liver Metastases in Newly Diagnosed Gastric Cancer: A Population-Based Study from SEER
Z. Sun (2019)
10.1007/s00761-020-00804-8
Behandlung des peritoneal metastasierten Magenkarzinoms
L. Feldbrügge (2020)
10.1002/bjs.11588
Treatment of PERItoneal disease in Stomach Cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results
R. T. van der Kaaij (2020)
10.4291/wjgp.v7.i3.283
"Magic" of our gastric cancer results on perioperative chemotherapy.
Carlos León-Espinoza (2016)
10.1016/j.ejso.2018.06.036
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis.
Cristina Rihuete Caro (2018)
10.1016/j.ejso.2015.03.231
Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis.
F. Coccolini (2015)
10.1080/02656736.2017.1387939
Exploring the trend in referrals for consideration of CRS and HIPEC to understand the attitudes of clinicians in the development of a national cancer centre programme in peritoneal disease
Weining Wang (2018)
10.1007/s11605-017-3533-8
SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors
J. Norton (2017)
10.21037/JGO-20-262
Intra-operative hyperthermic intraperitoneal chemotherapy for prevention and treatment of peritoneal metastases from gastric cancer: a narrative review
Zhong-He Ji (2020)
The registry of Hyperthermic Intraperitoneal Chemotherapy - a mandatory step in the development of this therapeutic approach in Romania.
Corneliu Lungoci (2015)
10.3747/co.23.2831
Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives.
J. Spiliotis (2016)
Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
UnitedHealthcare SignatureValue (2013)
10.3390/ijms21030951
Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach
Jin-On Jung (2020)
10.1007/s00595-020-02180-7
The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan
Toshiyuki Kitai (2020)
10.1016/j.gore.2020.100610
Concurrent hysterectomy and bilateral salpingo-oophorectomy during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for non-gynecologic cancers
McKayla J Riggs (2020)
10.1002/jso.24087
Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases
H. Shiozaki (2016)
10.1080/02656736.2017.1283065
Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases
Zhong-He Ji (2017)
10.1016/j.ejso.2016.04.053
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center.
H-T Wu (2016)
10.1002/jhbp.796
New metastasectomy criteria for peritoneal metastasis of hepatocellular carcinoma: A study of the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery
Hiroya Iida (2020)
10.3747/co.24.3736
Staging and surgical approaches in gastric cancer: a clinical practice guideline.
N. Coburn (2017)
10.21037/JGO-2020-04
Intraperitoneal chemotherapy in the treatment of gastric cancer peritoneal metastases: an overview of common therapeutic regimens
A. Brandl (2020)
Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) – Community Plan Medical Policy
(2020)
10.2217/fon-2017-0246
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.
L. Fornaro (2017)
10.7150/jca.28842
The survival benefit of palliative gastrectomy and/or metastasectomy in gastric cancer patients with synchronous metastasis: a population-based study using propensity score matching and coarsened exact matching
Lu-Ping Yang (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar